JJ Meier, K Hücking, JJ Holst, CF Deacon, … - Diabetes, 2001 - Am Diabetes Assoc In patients with type 2 diabetes, gastric inhibitory polypeptide (GIP) has lost
much of its insulinotropic activity. Whether this is similar in first-degree
relatives of patients with type 2 diabetes is unknown. A total of 21 first- ... Cited by 102 - Related articles - BL Direct - All 5 versions
T Vilsbøll, T Krarup, S Madsbad, J Holst - Diabetologia, 2002 - Springer Aims/hypothesis. Glucagon-like-peptide-1 (GLP-1) is strongly insulinotropic in
patients with Type II (non- insulin-dependent) diabetes mellitus, whereas glu-
cose-dependent insulinotropic polypeptide (GIP) is less effective. Our ... Cited by 135 - Related articles - BL Direct - All 4 versions
T Krarup, N Saurbrey, AJ Moody, C Kühl, S … - Metabolism: clinical and experimental, 1987 - ncbi.nlm.nih.gov The effect of highly purified natural porcine GIP on C-peptide release was
examined in six type I (insulin-dependent) diabetics (IDD) with residual
beta-cell function, six type II non-insulin-dependent) diabetics (NIDD), ... Cited by 41 - Related articles - All 3 versions
- ►diabetesjournals.org FC Lynn, N Pamir, EHC Ng, CHS McIntosh, TJ … - Diabetes, 2001 - Am Diabetes Assoc Glucose-dependent insulinotropic polypeptide (GIP) is a peptide hormone that is
released postprandially from the small intestine and acts in concert with
glucagon-like peptide (GLP)-1 to potentiate glucose-induced insulin ... Cited by 90 - Related articles - BL Direct - All 4 versions
JJ Holst, J Gromada, MA Nauck - Diabetologia, 1997 - Springer Carbohydrate ingestion causes the release of two in- sulinotropic intestinal
hormones, glucose-dependent insulinotropic polypeptide (GIP) [1] and glucagon-
like peptide-1 (GLP-1) [2]. GIP is mainly released from the duodenum, and ... Cited by 68 - Related articles - BL Direct - All 3 versions
- ►endojournals.org T Vilsboll, FK Knop, T Krarup, A Johansen, S … - Journal of Clinical Endocrinology & Metabolism, 2003 - Endocrine Soc The effect of the insulinotropic incretin hormone, glucagon-like peptide-1
(GLP-1), is preserved in typical middle-aged, obese, insulin-resistant type 2
diabetic patients, whereas a defective amplification of the so-called ... Cited by 77 - Related articles - BL Direct - All 4 versions
- ►endojournals.org CF Deacon, MA Nauck, J Meier, K Hucking, JJ … - Journal of Clinical Endocrinology & Metabolism, 2000 - Endocrine Soc Gastric inhibitory polypeptide (GIP) is susceptible to degradation, but only
recently has dipeptidyl peptidase IV been identified as the enzyme responsible.
Most RIAs recognize both intact GIP-(1–42) and the noninsulinotropic N- ... Cited by 173 - Related articles - BL Direct - All 4 versions
JJ Meier, B Gallwitz, N Siepmann, JJ Holst, … - Diabetologia, 2003 - Springer Aims/hypothesis. In the isolated perfused pancreas, gastric inhibitory
polypeptide (GIP) has been shown to enhance glucagon secretion at basal glucose
con- centrations, but in healthy humans no glucagonotropic effect of GIP ... Cited by 60 - Related articles - BL Direct - All 3 versions
MA Nauck, A El-Ouaghlidi, B Gabrys, K … - Regulatory peptides, 2004 - Elsevier Aims/Hypothesis: Since insulin secretion in response to exogenous gastric
inhibitory polypeptide (GIP) is diminished not only in patients with type 2
diabetes, but also in their normal glucose-tolerant first-degree relatives, ... Cited by 33 - Related articles - All 3 versions
B Nyholm, M Walker, CH Gravholt, PA Shearing, … - Diabetologia, 1999 - Springer Type II (non-insulin-dependent) diabetes mellitus is characterized by insulin
resistance, increased endoge- nous glucose production and beta-cell dysfunction
[1]. The latter has been shown in many ways, eg in response to mixed meals, ... Cited by 52 - Related articles - BL Direct - All 3 versions
